Find Information on a:
View all Postings for:
Search ClotCare
|
Postings on Outpatient Treatment
For Patients and Caregivers
|
Posting
|
Date Posted
|
|
INR Patient Self Testing Video Demo
|
October, 2009
|
|
Is it Safe to Send Stable Anticoagulation Clinic Patients Back to Usual Medical Care? No!
|
April, 2008
|
|
Should 3rd Generation Birth Control Pills be Banned? - Petition to Ban 3rd Generation OCs due to Increased Clotting Risk
|
March, 2007
|
|
Should 3rd Generation Birth Control Pills be Banned? - Opposition to a Petition to Ban 3rd Generation OCs
|
March, 2007
|
|
Telephone Versus In-Office Anticoagulation Management
|
January, 2007
|
|
The Pulmonary Embolism Support Group - Support for Individuals with DVT or PE
|
January, 2007
|
|
Cedric Bills' DVT Story
|
March, 2006
|
|
Largest study yet confirms benefits of clinical pharmacy managed anticoagulation service
|
June, 2005
|
|
FDA Rejects Ximelagatran (brand name Exanta)
|
October, 2004
|
|
Patient Self Testing
|
May, 2004
|
|
Understanding Atrial Fibrillation
|
|
For Health Care Providers
|
Posting
|
Date Posted
|
|
New study and accompanying editorial suggest that warfarin may be indicated in fewer patients, but (as usual) issues remain
|
January, 2010
|
|
INR Patient Self Testing Video Demo
|
October, 2009
|
|
Is it Safe to Send Stable Anticoagulation Clinic Patients Back to Usual Medical Care? No!
|
April, 2008
|
|
Warfarin more effective and at least as safe as low dose aspirin in elderly patients with atrial fibrillation
|
September, 2007
|
|
Should we shorten treatment of DVT and PE to 3 months? Not yet.
|
April, 2007
|
|
Should 3rd Generation Birth Control Pills be Banned? - Petition to Ban 3rd Generation OCs due to Increased Clotting Risk
|
March, 2007
|
|
Should 3rd Generation Birth Control Pills be Banned? - Opposition to a Petition to Ban 3rd Generation OCs
|
March, 2007
|
|
Should we be treating fewer patients with warfarin (Coumadin)?
|
March, 2007
|
|
Should we be treating more patients with warfarin (Coumadin)?
|
March, 2007
|
|
Telephone Versus In-Office Anticoagulation Management
|
January, 2007
|
|
The Pulmonary Embolism Support Group - Support for Individuals with DVT or PE
|
January, 2007
|
|
d-Dimer Found Useful in Decision to Continue Anticoagulation Following First Idiopathic VTE
|
December, 2006
|
|
Major Bleeding Events Lead to Under Use of Anticoagulation in Atrial Fibrillation, but Ischemic Strokes do not Alter Prescribing Practices
|
February, 2006
|
|
Daily Low-dose Vitamin K Supplementation Stabilizes INRs
|
February, 2006
|
|
Poor Early Anticoagulation Control Associated with Near 3-fold Increase in DVT Recurrence and Post-thrombotic Syndrome
|
January, 2006
|
|
Risk and Benefits of Aspirin in Primary Prevention in Both Men and Women Better Defined
|
January, 2006
|
|
New Data Fuels Continued Controversy About Anti-Phospholipid Antibody (APA) and Lupus Anticoagulant Management (LAC)
|
November, 2005
|
|
Appropriate Use of Anticoagulation in Atrial Fibrillation Patients Dramatically Increased with Availability of Anticoagulation Management Service
|
October, 2005
|
|
Advanced age affects major bleeding and major thromboembolic rates in patients with high target INRs
|
October, 2005
|
|
Anticoagulation Training Programs
|
September, 2005
|
|
What Happened to Ximelagatran?
|
March, 2005
|
|
New Study Supports INR of 2 to 3 for Elderly Patients with A. Fib.
|
November, 2004
|
|
FDA Rejects Ximelagatran (brand name Exanta)
|
October, 2004
|
|
Study and Editorial Address Three-Fold Greater Recurrence of DVT in Men
|
September, 2004
|
|
New Supplement Devoted to Factor Xa Inhibitors (fondaparinux)
|
August, 2004
|
|
New Anticoagulants to Displace or Reshape Anticoagulation Clinics
|
April, 2004
|
|
Fondaparinux, LMWH, or UFH for PE?
|
February, 2004
|
|
Low Molecular Weight Heparin Preferred for Pulmonary Embolism?
|
February, 2004
|
|
Ximelagatran (brand name Exanta) is Leading the Coming Revolution in Stroke Prevention in Atrial Fibrillation -- Two New Studies
|
January, 2004
|
|
|
ClotCare Online Resource covers topics such as Coumadin, warfarin, blood clot, stroke, heart attack, INR, PT, low molecular weight haparin, heparin, dvt, anticoagulation, antithrombotic therapy, A. fib, atrial fibrillation, heart valve, heart valve replacement, vitamin k, AstraZeneca, Aventis, CE credit, and more.
|